CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Parkinson's disease - Management
How is amantadine used in secondary care?
Amantadine
- Is an antiviral drug with relatively weak anti-parkinsonian activity. Its mechanism of action has not been established.
- May be used as an adjuvant to levodopa in the management of dyskinesias in later Parkinson's disease.
- May rarely be used in early, mild Parkinson's disease.
- Has a lack of evidence on safety and efficacy, and trials have been of poor quality.
[National Collaborating Centre for Chronic Conditions, 2006]
© NHS Institute for Innovation and Improvement